Want to see HKMPY full AI Analyst Report?
Hikma Pharmaceuticals (HKMPY) Ratios
Hikma Pharmaceuticals Ratios
HKMPY's free cash flow for Q2 2026 was $46.99M. For the 2026 fiscal year, HKMPY's free cash flow was decreased by $-121.98M and operating cash flow was $168.97M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.82 | 1.14 | 1.57 | 1.86 | 2.06 |
| Quick Ratio | 1.06 | 0.65 | 0.90 | 1.14 | 1.38 |
| Cash Ratio | 0.23 | 0.10 | 0.15 | 0.25 | 0.42 |
| Solvency Ratio | 0.20 | 0.20 | 0.15 | 0.16 | 0.31 |
| Operating Cash Flow Ratio | 0.25 | 0.29 | 0.45 | 0.49 | 0.63 |
| Short-Term Operating Cash Flow Coverage | 3.39 | 0.88 | 4.05 | 3.81 | 5.70 |
| Net Current Asset Value | $ -422.00M | $ -549.00M | $ -371.00M | $ -324.00M | $ 189.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.25 | 0.25 | 0.29 | 0.19 |
| Debt-to-Equity Ratio | 0.62 | 0.57 | 0.54 | 0.60 | 0.34 |
| Debt-to-Capital Ratio | 0.38 | 0.36 | 0.35 | 0.38 | 0.26 |
| Long-Term Debt-to-Capital Ratio | 0.36 | 0.21 | 0.31 | 0.33 | 0.21 |
| Financial Leverage Ratio | 2.19 | 2.22 | 2.13 | 2.09 | 1.78 |
| Debt Service Coverage Ratio | 3.15 | 0.87 | 1.98 | 3.09 | 3.55 |
| Interest Coverage Ratio | 5.36 | 6.95 | 4.22 | 4.03 | 8.43 |
| Debt to Market Cap | 0.34 | 0.23 | 0.22 | 0.29 | 0.11 |
| Interest Debt Per Share | 15.51 | 12.60 | 11.49 | 12.10 | 7.92 |
| Net Debt to EBITDA | 1.63 | 1.54 | 1.76 | 1.47 | 0.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 42.93% | 45.25% | 48.94% | 49.19% | 50.96% |
| EBIT Margin | 16.96% | 16.95% | 12.80% | 19.79% | 23.46% |
| EBITDA Margin | 23.29% | 23.25% | 19.44% | 27.33% | 30.00% |
| Operating Profit Margin | 16.96% | 19.57% | 12.77% | 11.20% | 22.80% |
| Pretax Profit Margin | 15.50% | 14.52% | 9.77% | 9.26% | 21.27% |
| Net Profit Margin | 12.00% | 11.48% | 6.61% | 7.47% | 16.49% |
| Continuous Operations Profit Margin | 12.15% | 11.54% | 6.68% | 7.59% | 16.41% |
| Net Income Per EBT | 77.46% | 79.07% | 67.62% | 80.69% | 77.53% |
| EBT Per EBIT | 91.37% | 74.18% | 76.57% | 82.62% | 93.30% |
| Return on Assets (ROA) | 7.11% | 6.99% | 4.06% | 4.20% | 9.63% |
| Return on Equity (ROE) | 15.54% | 15.54% | 8.64% | 8.81% | 17.16% |
| Return on Capital Employed (ROCE) | 13.50% | 19.40% | 10.98% | 8.31% | 17.34% |
| Return on Invested Capital (ROIC) | 10.31% | 12.78% | 7.16% | 6.53% | 12.92% |
| Return on Tangible Assets | 8.95% | 9.03% | 5.31% | 5.62% | 12.10% |
| Earnings Yield | 8.71% | 6.49% | 3.76% | 4.55% | 6.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.11 | 3.46 | 3.64 | 3.24 | 3.26 |
| Payables Turnover | 2.67 | 4.78 | 4.75 | 4.40 | 4.78 |
| Inventory Turnover | 1.73 | 1.74 | 1.65 | 1.65 | 1.80 |
| Fixed Asset Turnover | 2.32 | 2.36 | 2.52 | 2.33 | 2.23 |
| Asset Turnover | 0.59 | 0.61 | 0.61 | 0.56 | 0.58 |
| Working Capital Turnover Ratio | 4.55 | 5.98 | 3.42 | 2.52 | 2.59 |
| Cash Conversion Cycle | 192.12 | 239.53 | 244.88 | 251.08 | 238.32 |
| Days of Sales Outstanding | 117.32 | 105.64 | 100.17 | 112.68 | 112.09 |
| Days of Inventory Outstanding | 211.58 | 210.22 | 221.54 | 221.45 | 202.62 |
| Days of Payables Outstanding | 136.78 | 76.33 | 76.83 | 83.05 | 76.38 |
| Operating Cycle | 328.90 | 315.85 | 321.70 | 334.13 | 314.70 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.26 | 5.10 | 5.47 | 4.74 | 5.52 |
| Free Cash Flow Per Share | 1.47 | 2.97 | 3.63 | 2.73 | 3.54 |
| Dividend Paid and CapEx Coverage Ratio | 0.94 | 1.38 | 1.78 | 1.51 | 1.83 |
| Capital Expenditure Coverage Ratio | 1.82 | 2.40 | 2.98 | 2.36 | 2.79 |
| Operating Cash Flow Coverage Ratio | 0.22 | 0.43 | 0.51 | 0.41 | 0.75 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.18 | 0.21 | 0.21 | 0.25 |
| Free Cash Flow Yield | 3.51% | 5.94% | 8.00% | 7.38% | 5.88% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.46 | 15.44 | 26.57 | 21.99 | 16.53 |
| Price-to-Sales (P/S) Ratio | 1.38 | 1.77 | 1.76 | 1.64 | 2.73 |
| Price-to-Book (P/B) Ratio | 1.78 | 2.40 | 2.30 | 1.94 | 2.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 28.48 | 16.82 | 12.50 | 13.55 | 17.01 |
| Price-to-Operating Cash Flow Ratio | 12.85 | 9.81 | 8.30 | 7.80 | 10.91 |
| Price-to-Earnings Growth (PEG) Ratio | 0.88 | 0.17 | 22.32 | -0.41 | -30.25 |
| Enterprise Value Multiple | 7.55 | 9.15 | 10.80 | 7.48 | 9.63 |
| Enterprise Value | 5.90B | 6.65B | 6.03B | 5.15B | 7.38B |
| EV to EBITDA | 7.55 | 9.15 | 10.80 | 7.48 | 9.63 |
| EV to Sales | 1.76 | 2.13 | 2.10 | 2.04 | 2.89 |
| EV to Free Cash Flow | 36.34 | 20.22 | 14.94 | 16.87 | 18.04 |
| EV to Operating Cash Flow | 16.40 | 11.80 | 9.93 | 9.71 | 11.57 |
| Tangible Book Value Per Share | 13.02 | 10.53 | 9.97 | 9.15 | 13.64 |
| Shareholders’ Equity Per Share | 23.51 | 20.87 | 19.77 | 19.09 | 21.24 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.22 | 0.20 | 0.32 | 0.18 | 0.23 |
| Revenue Per Share | 30.44 | 28.26 | 25.86 | 22.50 | 22.10 |
| Net Income Per Share | 3.65 | 3.24 | 1.71 | 1.68 | 3.65 |
| Tax Burden | 0.77 | 0.79 | 0.68 | 0.81 | 0.78 |
| Interest Burden | 0.91 | 0.86 | 0.76 | 0.47 | 0.91 |
| Research & Development to Revenue | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 |
| SG&A to Revenue | 0.17 | 0.18 | 0.22 | 0.20 | 0.19 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Income Quality | 0.89 | 1.24 | 2.16 | 2.27 | 1.17 |
Currency in USD